tradingkey.logo

CorMedix Inc

CRMD
9.810USD
+0.160+1.66%
收盘 11/28, 13:00美东报价延迟15分钟
768.60M总市值
4.73市盈率 TTM

CorMedix Inc

9.810
+0.160+1.66%

关于 CorMedix Inc 公司

CorMedix Inc. 是一家生物制药公司。该公司专注于开发和商业化用于预防和治疗危及生命的病症和疾病的治疗产品。该公司专注于商业化其主打产品 DefenCath,这是一种抗菌导管锁定溶液,经批准用于降低通过中央静脉导管接受慢性血液透析的肾衰竭成年患者的导管相关血流感染发生率。DefenCath 是一种由 13.5 mg/mL 牛磺罗定和 1000 USP 单位/mL 肝素组成的配方,用于降低通过中央静脉导管 (CVC) 接受慢性血液透析的肾衰竭成年患者的导管相关血流感染 (CRBSI) 发生率。除了 DefenCath 之外,该公司还赞助了一项临床前研究合作,以研究牛磺罗定作为罕见儿科肿瘤的潜在治疗方法。

CorMedix Inc简介

公司代码CRMD
公司名称CorMedix Inc
上市日期Mar 25, 2010
CEOMr. Joseph Todisco
员工数量64
证券类型Ordinary Share
年结日Mar 25
公司地址300 Connell Drive
城市BERKELEY HEIGHTS
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编07922
电话19085179500
网址https://cormedix.com/
公司代码CRMD
上市日期Mar 25, 2010
CEOMr. Joseph Todisco

CorMedix Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
--
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
--
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
-56.10%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
--
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
--
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
--
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
--
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
-56.10%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
--

收入明细

FY2025Q2
FY2025Q1
FY2024
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
39.74M
0.00%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.40%
Abdalkader (Shaibatalhamd Aymen)
5.90%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
Deerfield Management Company, L.P.
4.22%
其他
74.05%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.40%
Abdalkader (Shaibatalhamd Aymen)
5.90%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
Deerfield Management Company, L.P.
4.22%
其他
74.05%
股东类型
持股股东
占比
Investment Advisor
25.96%
Investment Advisor/Hedge Fund
15.18%
Hedge Fund
11.14%
Individual Investor
7.05%
Research Firm
2.03%
Pension Fund
0.97%
Bank and Trust
0.33%
Insurance Company
0.03%
Venture Capital
0.03%
其他
37.28%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
313
36.30M
46.33%
+3.65M
2025Q2
280
26.40M
35.51%
-7.69M
2025Q1
281
29.73M
44.27%
-179.25K
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
4.80M
6.42%
+485.88K
+11.27%
Jun 30, 2025
Abdalkader (Shaibatalhamd Aymen)
4.65M
6.22%
+4.65M
--
Aug 08, 2025
The Vanguard Group, Inc.
4.31M
5.77%
+675.49K
+18.59%
Jun 30, 2025
Marshall Wace LLP
2.58M
3.46%
+2.35M
+1019.17%
Jun 30, 2025
State Street Investment Management (US)
1.60M
2.15%
+62.52K
+4.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.60M
2.14%
+163.40K
+11.40%
Jun 30, 2025
Citadel Advisors LLC
1.71M
2.3%
+1.61M
+1517.64%
Jun 30, 2025
Alyeska Investment Group, L.P.
750.00K
1%
+750.00K
--
Jun 30, 2025
查看更多

持股ETF

更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Invesco Biotechnology & Genome ETF
2.22%
SPDR S&P Pharmaceuticals ETF
1.94%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.45%
VictoryShares Small Cap Free Cash Flow ETF
0.74%
First Trust Active Factor Small Cap ETF
0.35%
Janus Henderson Small Cap Growth Alpha ETF
0.26%
ALPS Barron's 400 ETF
0.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.22%
Vanguard US Multifactor ETF
0.18%
iShares Micro-Cap ETF
0.16%
查看更多
Invesco Biotechnology & Genome ETF
占比2.22%
SPDR S&P Pharmaceuticals ETF
占比1.94%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.45%
VictoryShares Small Cap Free Cash Flow ETF
占比0.74%
First Trust Active Factor Small Cap ETF
占比0.35%
Janus Henderson Small Cap Growth Alpha ETF
占比0.26%
ALPS Barron's 400 ETF
占比0.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0.22%
Vanguard US Multifactor ETF
占比0.18%
iShares Micro-Cap ETF
占比0.16%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

CorMedix Inc的前五大股东是谁?

CorMedix Inc 的前五大股东如下:
BlackRock Institutional Trust Company, N.A.持有股份:4.80M,占总股份比例:6.42%。
Abdalkader (Shaibatalhamd Aymen)持有股份:4.65M,占总股份比例:6.22%。
The Vanguard Group, Inc.持有股份:4.31M,占总股份比例:5.77%。
Marshall Wace LLP持有股份:2.58M,占总股份比例:3.46%。
State Street Investment Management (US)持有股份:1.60M,占总股份比例:2.15%。

CorMedix Inc的前三大股东类型是什么?

CorMedix Inc 的前三大股东类型分别是:
BlackRock Institutional Trust Company, N.A.
Abdalkader (Shaibatalhamd Aymen)
The Vanguard Group, Inc.

有多少机构持有CorMedix Inc(CRMD)的股份?

截至2025Q3,共有313家机构持有CorMedix Inc的股份,合计持有的股份价值约为36.30M,占公司总股份的46.33%。与2025Q2相比,机构持股有所增加,增幅为10.82%。

哪个业务部门对CorMedix Inc的收入贡献最大?

在FY2025Q2,--业务部门对CorMedix Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI